US Senators said Wednesday coronavirus patients could lose coverage if the ACA is abolished by a new Supreme Court, while Sen. Warren accused a COVID-19 response advisor of conflicts of interest.
Legislators on 23 September asked several Trump administration officials if infection with COVID-19 can be considered a preexisting condition that would be no longer coverable if the Affordable Care Act is struck down by a more conservative Supreme Court, and if asymptomatic people should be tested for the virus, or not.
The lawmakers spoke at a Senate Health, Education, Labor and Pensions (HELP) Committee hearing on progress in fighting the COVID-19...
Just a year and four months after publishing a final rule that would have allowed it to regulate laboratory developed tests as medical devices, the US FDA has rescinded the controversial measure, finally putting an end to the saga.
At an Aug. 4 public meeting on MDUFA VI, FDA officials, industry representatives, and patient advocates outlined their priorities for the next user fee agreement, highlighting goals such as improved transparency, streamlined reviews, enhanced safety measures, and greater patient involvement.
Pending legislation seeks to address what the sponsors argue is a lack of transparency in medical billing. If enacted, the bill would provide patients with the costs of procedures and medications before receiving them. A data collection expert discusses what the bill could mean for patients.
NHS England's national chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.
The US FDA has cleared NeuroOne's OneRF trigeminal nerve ablation system for the treatment of trigeminal neuralgia. This minimally invasive method utilizes radio frequency energy to alleviate pain, offering an alternative to traditional medications and surgeries. A fall commercial launch is planned.
The US FDA posted three warning letters in July, covering medical supply kits, wearables and orthopedics.
After receiving FDA clearance for its Genio sleep apnea implant, Nyxoah plans a major US rollout despite a patent suit from rival Inspire Medical. Genio offers bilateral nerve stimulation as a CPAP alternative, with strong trial results.
